Research

Research
The IMO is at the forefront of research into the latest developments and contributes to the main clinical trials of the day as a member of the EVICR (European Vision Institute Clinical Research Network). The IMO’s leadership and innovative approach are also reflected in a unique and pioneering commitment to translational research, in which ophthalmologists and geneticists work side by side to advance faster in the prevention, diagnosis and treatment of hereditary eye diseases.

Research in IMO

The IMO is at the forefront of research into the latest developments and contributes to the main clinical trials of the day as a member of the EVICR (European Vision Institute Clinical Research Network). The IMO’s leadership and innovative approach are also reflected in a unique and pioneering commitment to translational research, in which ophthalmologists and geneticists work side by side to advance faster in the prevention, diagnosis and treatment of hereditary eye diseases.

Ongoing projects

In the field of clinical research, the objective of projects currently under development is not only to improve the prognosis of patients with certain diseases, but also to offer, for the first time, an effective solution to diseases that are currently untreatable. This is also the ultimate goal of genetic studies, whose aim is to provide in-depth analysis of already known genes and identify new genes related to retinal dystrophies.
Investigación básica

Mass sequencing of exomes for the identification of new genes and variants responsible for retinal dystrophies

Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.

Investigación clínica

VIOLET

An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME)

Investigación clínica

Spectri

Phase III, multicentre, randomised, double-blind, sham-controlled trial to assess the efficacy and safety of lampalizumab administered by intravitreal injection to patients with geographic atrophy secondary to age-related macular degeneration.

Project history

The ophthalmologists, optometrists and nurses who specialise in ocular photography at the IMO carry out several multicentre clinical trials a year, of which the IMO is often the coordinator or main leading centre in Spain. These trials join the pioneering projects carried out by the genetics laboratory.
Investigación clínica

Duoprost

Phase III: Assessment of the efficacy and safety of a fixed combination of unpreserved latanoprost drops and timolol 0.5% (T2347) versus Xalacom® in patients with ocular hypertension or glaucoma.